The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studies
Abstract
Objective: To assess the efficacy and safety of VX‐702, a p38 MAPK inhibitor, in patients with active, moderate‐to‐severe rheumatoid arthritis (RA). Methods: Two 12‐week, double‐blind, placebo‐controlled studies of VX‐702 were conducted in patients with active, moderate‐to‐severe RA. In the VeRA study, 313 patients received placebo or 2 daily doses of VX‐702. In Study 304, 117 patients received placebo, daily VX‐702, or twice weekly VX‐702 in addition to concomitant methotrexate (MTX). Study end points included the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (an ACR20 response), ACR50 and ACR70 responses, changes in the serum levels of biomarkers of inflammation, and safety assessments. Results: The numerically superior ACR20 response rates among patients receiving VX‐702 compared with those receiving placebo in both studies did not reach pairwise statistical significance at the highest doses in either study. At week 12 in the VeRA study, ACR20 response rates were 40%, 36%, and 28% among patients receiving 10 mg of VX‐702, 5 mg of VX‐702, and placebo, respectively. In Study 304, the response rates were 40%, 44%, and 22% for patients receiving 10 mg VX‐702 daily plus MTX, 10 mg VX‐702 twice weekly plus MTX, and placebo, respectively. Reductions in the levels of C‐reactive protein, soluble tumor necrosis factor receptor p55, and serum amyloid A were observed as early as week 1 in both studies, but these levels rapidly returned to baseline values by week 4. The overall frequency of adverse events was similar between the VX‐702 and placebo groups. In the VeRA study, serious infections were more frequent in the VX‐702 groups compared with the placebo group (2.4% versus 0%) but not in Study 304 (2.6% versus 4.9%). Conclusion: The modest clinical efficacy plus the transient suppression of biomarkers of inflammation observed in this study suggest that p38 MAPK inhibition may not provide meaningful, sustained suppression of the chronic inflammation seen in RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis
Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H.-D., & Gaestel, M. (1999) · Nature Cell Biology · doi:10.1038/10061 · Cited by 763
Cited by
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
Bartok, B., & Firestein, G. S. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00859.x · Cited by 1,906
Mitogen-activated protein kinases in innate immunity
Arthur, J. S. C., & Ley, S. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3495 · Cited by 1,855
Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors
Bottini, N., & Firestein, G. S. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.190 · Cited by 907
Rose, B. A., Force, T., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 723
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Metadata
- Authors
- Damjanov, N., Kauffman, R. S., & Spencer‐Green, G. T.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-04-29
- Volume
- 60
- Issue
- 5
- Pages
- 1232-1241
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1977683934
- Cited by
- 242
- References
- 1
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studies. https://app.cochat.ai/papers/10.1002/art.24485
- The paper
- Damjanov, N., Kauffman, R. S., & Spencer‐Green, G. T. (2009). Efficacy, pharmacodynamics, and safety of VX‐702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double‐blind, placebo‐controlled clinical studies. Arthritis & Rheumatism. https://doi.org/10.1002/art.24485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.